Parkinson’s UK’s support for horrific experiments on monkeys

Posted on the 28th September 2018

Animal Aid has discovered that Parkinson’s UK will provide funding of more than £780,000 for work which will include testing a drug named NLX-112 on primates.

The funding will be provided through their drug development arm: ‘Virtual Biotech’ and the work will be in partnership with a drug company – Neurolixis – and King’s College London, which has a colony of marmoset monkeys. Parkinson’s UK stated on their website that the work would include ‘safety and efficacy testing in a marmoset model of Parkinson’s’.

Although there are no details of exactly what the monkeys will suffer, the usual way in which Parkinson’s is ‘modelled’ in marmosets is by giving them a series of injections of a chemical called MPTP. This is known to cause severely debilitating, distressing effects and Parkinson-like symptoms, including paralysis and total loss (or extreme slowness) of movement, rigidity, loss of vocalisation, lack of muscle movement including eye rigidity, lack of coordination, uncontrollable body tremors and a hunched posture.

We have previously reported how, at this stage, monkeys have been force-fed, over many days, with L-DOPA, a drug for Parkinson’s Disease, to induce symptoms of dyskinesia (uncontrollable body spasms, writhing and twisted body posture). Once these symptoms are present, a drug or some other intervention will typically be given to attempt to alleviate them.

The drug being tested was developed for L-DOPA–induced dyskinesia.

Please contact Parkinson’s UK to urge them to stop these terrible experiments

Read more posts...

Vegan advert banned by ASA for showing the truth

An advert by Vegan Friendly UK, in collaboration with vegan food brand Miami Kitchen, was banned by the Advertising Standards Agency (ASA) following 63 complaints about its content.

Posted 19 Jun 2022